1. "2020"
Formats
  1. Journal Article (2337)
  2. Meeting Abstract (1901)
  3. Review (494)
  4. Editorial (342)
  5. Correspondence (121)
  6. Guidelines (114)
  7. Book Section (99)
  8. Research Letter (95)
  9. Miscellaneous (61)
  10. Conference Paper (33)
  11. Book Whole (2)
Groups
  1. Department of Medicine (2560)
  2. Solid Tumor Oncology Division (1535)
  3. GSK Faculty (1257)
  4. Sloan Kettering Institute Postdocs (1240)
  5. Hematologic Malignancies, Division of (936)
  6. Survivorship Research (930)

More Groups

People
  1. Jorge Reis-Filho (93)
  2. Miguel-Angel Perales (93)
  3. Sergio Giralt (91)
  4. Alexander Drilon (81)
  5. Britta Weigelt (76)
  6. Nadeem Abu-Rustum (71)

More People

Years
  1. 2020 (5599)
Publications
  1. Journal of Clinical Oncology (500)
  2. Blood (212)
  3. Cancer Research (185)
  4. Annals of Oncology (152)
  5. International Journal of Radiation Oncology, Biology, Physics (129)
  6. Laboratory Investigation (116)

More Publications

Publishers
  1. Elsevier Inc. (714)
  2. American Society of Clinical Oncology (548)
  3. Nature Publishing Group (385)
  4. American Association for Cancer Research (357)
  5. Oxford University Press (356)
  6. Springer (342)

More Publishers

Results (5599)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and renal impairment
    Meeting Abstract

    Kortüm, M.; Lee, H. C.; Cohen, A. D.; Chari, A.; Hultcrantz, M.; Nooka, A. K.; Callander, N.; Suvannasankha, A.; Badros, A.; Libby, E.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Clinical activity of cabozantinib in patients with advanced hepatocellular carcinoma previously treated with anti-VEGF and immuno-oncology therapy: Subgroup analysis from the phase 3 CELESTIAL trial
    Meeting Abstract

    Trojan, J.; Abou-Alfa, G. K.; Cheng, A. L.; Saletan, S.; Kelley, R. K.; El-Khoueiry, A. B.
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Combined JAK2 and ERK1/2 kinase inhibition as a novel therapeutic approach in myeloproliferative neoplasms
    Meeting Abstract

    Brkic, S.; Stivala, S.; Santopolo, A.; Jungius, S.; Passweg, J. R.; Tsakiris, D.; Dirnhofer, S.; Levine, R. L.; Meyer, S. C.
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Resistance to type II JAK2 inhibition in MPN is dependent on MEK-ERK activation and is targetable
    Meeting Abstract

    Codilupi, T.; Szybinski, J.; Wicki, A.; Yang, J. L.; Ghosh, N.; Passweg, J.; Tsakiris, D.; Levine, R. L.; Koche, R.; Meyer, S. C.
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Exploratory analysis of retreatment with brentuximab vedotin (BV) after frontline treatment with brentuximab vedotin and CHP (A+CHP) for patients (pts) with CD30+ peripheral T-cell lymphoma (ECHELON-2)
    Meeting Abstract

    Trümper, L.; Pro, B.; Horwitz, S.; O'connor, O.; Tilly, H.; Choi, I.; Gritti, G.; Fox, C.; Alpdogan, O.; Mayer, J.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Single-cell multiplex immunofluorescence of formalin-fixed, paraffin-embedded prostate cancer tissue identifies PI3K pathway activation in two prospective cohort studies
    Meeting Abstract

    Stopsack, K. H.; Huang, Y.; Tyekucheva, S.; Gerke, T. A.; Bango, C.; Elfandy, H.; Gao, X.; Cai, Z.; Roberts, T. M.; Kantoff, P. W.; more...
    Molecular Cancer Research (2020)

    Fulltext@MSK | Save
  • Activating alterations of p110 subunits determine PI3K isoform selectivity in prostate cancer
    Meeting Abstract

    Zhang, Z.; Mao, N.; Lee, Y. S.; Li, D.; Rosen, N.; Sawyers, C.; Carver, B.
    Molecular Cancer Research (2020)

    Fulltext@MSK | Save
  • Dual genetic targeting of ERK1 and ERK2 abrogates the competitive potential of the myeloproliferative neoplasm clone
    Meeting Abstract

    Stivala, S.; Brkic, S.; Santopolo, A.; Dirnhofer, S.; Passweg, J.; Tsakiris, D.; Neel, B.; Levine, R.; Meyer, S.
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Single-arm, open-label, phase II study of LY3023414 for the treatment of recurrent or persistent endometrial cancer
    Meeting Abstract

    Rubinstein, M. M.; Hyman, D.; Caird, I.; O'Cearbhaill, R.; Grisham, R.; Tew, W.; Hensley, M.; Sabbatini, P.; Aghajanian, C.; Iasonos, A.; more...
    Molecular Cancer Research (2020)

    Fulltext@MSK | Save
  • Predicting gemcitabine uptake by (18)F-FAC in murine models of pancreatic cancer
    Meeting Abstract

    Russell, J.; Grkovski, M.; Pillarsetty, N.; LeKaye, C.; O'Donoghue, I.; Humm, J.
    Journal of Nuclear Medicine (2020)

    Fulltext@MSK | Save